Eric Hyllengren
Vermogen: 147 630 $ op 31-07-2026
Vermogen: 147 630 $ op 31-07-2026
Mr. Eric Hyllengren is a Chief Financial & Accounting Officer at Tenaya Therapeutics, Inc. Mr. Hyllengren was previously employed as a Chief Financial & Accounting Officer by Zura Bio Ltd., a Chief Financial, Operating & Accounting Officer by Atara Biotherapeutics, Inc., and an Executive Director-Business Development by Amgen, Inc. He received his undergraduate degree from the University of Notre Dame and an MBA from Kellogg School of Management.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 10-03-2026 | 17.617 ( 0,2% ) | 147 630 $ | 31-07-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| TENAYA THERAPEUTICS, INC. | Financieel Directeur/CFO | 13-07-2026 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ZURA BIO LIMITED | Financieel Directeur/CFO | 20-04-2026 |
| ATARA BIOTHERAPEUTICS, INC. | Financieel Directeur/CFO | 31-03-2025 |
| AMGEN INC. | Corporate Officer/Principal | 01-01-2018 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 6 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
University of Notre Dame
University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kellogg School of Management
Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for heart failure | Health Technology |
Zura Bio Ltd.
Zura Bio Ltd. BiotechnologyHealth Technology Operates as a multi-asset clinical-stage biotechnology company that focuses on develops novel medicines for immune and inflammatory disorders | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau